GEN Exclusives

More »

GEN News Highlights

More »
Apr 18, 2007

Avanir’s Value More Than Doubled on Phase III Results of Diabetic Neuropathic Pain Drug

  • Avanir Pharmaceuticals reported positive results from the Phase III evaluation of its diabetic neuropathic pain drug. The company’s shares soared 165% to open trading at $3.37.

    Zenvia (dextromethorphan hydrobromide/quinidine sulfate (DMQ)) is an NMDA antagonist and sigma-1 agonist. In the trial, two doses of Zenvia, 45/30 mg DMQ and 30/30 mg DMQ, both dosed twice daily, were compared to placebo. Both treatment groups had lower pain ratings than placebo patients. The drug also showed statistically significant improvements in a number of secondary endpoints, including pain relief and pain intensity.

    Zenvia is also in development for the treatment of involuntary emotional expression disorder.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?